Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
JAZZ 
Jazz Pharmaceuticals PLC (JAZZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/29/2025: JAZZ (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
18 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $188.12
1 Year Target Price $188.12
| 10 | Strong Buy |
| 6 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -0.25% | Avg. Invested days 42 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/29/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.23B USD | Price to earnings Ratio - | 1Y Target Price 188.12 |
Price to earnings Ratio - | 1Y Target Price 188.12 | ||
Volume (30-day avg) 18 | Beta 0.28 | 52 Weeks Range 95.49 - 148.06 | Updated Date 10/29/2025 |
52 Weeks Range 95.49 - 148.06 | Updated Date 10/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.98 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When - | Estimate 5.96 | Actual - |
Profitability
Profit Margin -9.91% | Operating Margin (TTM) 20.94% |
Management Effectiveness
Return on Assets (TTM) 5.19% | Return on Equity (TTM) -10.84% |
Valuation
Trailing PE - | Forward PE 6.9 | Enterprise Value 12086199182 | Price to Sales(TTM) 2.01 |
Enterprise Value 12086199182 | Price to Sales(TTM) 2.01 | ||
Enterprise Value to Revenue 2.96 | Enterprise Value to EBITDA 32.47 | Shares Outstanding 60658809 | Shares Floating 58681332 |
Shares Outstanding 60658809 | Shares Floating 58681332 | ||
Percent Insiders 3.07 | Percent Institutions 104.55 |
Upturn AI SWOT
Jazz Pharmaceuticals PLC
Company Overview
History and Background
Jazz Pharmaceuticals PLC was founded in 2003. It initially focused on developing treatments for sleep disorders. Through strategic acquisitions and internal development, it has expanded its portfolio to include oncology and other specialty areas.
Core Business Areas
- Sleep: Development and commercialization of treatments for sleep disorders, including narcolepsy and idiopathic hypersomnia.
- Oncology: Development and commercialization of treatments for hematologic and solid tumors.
- Other: Includes development and commercialization of treatments for rare diseases and other specialty areas.
Leadership and Structure
Bruce Cozadd serves as Chairman and CEO. The company has a structured organizational framework with departments focused on research and development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Xyrem/Xywav: Sodium oxybate/calcium, magnesium, potassium, and sodium oxybates oral solution for narcolepsy. Faces competition from generic versions and other stimulants. Total Xywav revenue $1.2 Billion as of Dec 31, 2023. Competitors: Avadel Pharmaceuticals (FTXP) with Lumryz and generic forms of Xyrem.
- revenue: 1200000000
- Epidiolex/Epidyolex: Cannabidiol (CBD) oral solution for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Faces competition from other anti-epileptic drugs. Total Epidiolex revenue $737.7 million as of Dec 31, 2023. Competitors: GW Pharmaceuticals (acquired by Jazz), Zogenix (now UCB).
- revenue: 737700000
- Rylaze: Asparaginase erwinia chrysanthemi (recombinant)-rywn for acute lymphoblastic leukemia (ALL). Competitors: ERYTECH Pharma S.A.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. It is characterized by extensive research and development, patent protection, and regulatory approvals.
Positioning
Jazz Pharmaceuticals PLC is a specialty pharmaceutical company focused on sleep medicine and oncology. Its competitive advantage lies in its proprietary products and established market presence.
Total Addressable Market (TAM)
The TAM for sleep disorder and oncology treatments is substantial, estimated to be in the tens of billions of dollars. Jazz is positioned to capture a share of this market with its focused portfolio.
Upturn SWOT Analysis
Strengths
- Proprietary product portfolio
- Established market presence in sleep medicine
- Strong financial performance
- Experienced management team
- Successful acquisition track record
Weaknesses
- Reliance on key products
- Exposure to generic competition
- Regulatory risks
- High R&D costs
- Debt burden
Opportunities
- Expansion into new therapeutic areas
- Geographic expansion
- Strategic acquisitions
- Development of innovative therapies
- Partnerships
Threats
- Generic competition
- Pricing pressure
- Regulatory changes
- Clinical trial failures
- Economic downturn
Competitors and Market Share
Key Competitors
- VTRS
- TEVA
- FTXP
- UCB
Competitive Landscape
Jazz Pharmaceuticals PLC faces intense competition from both established pharmaceutical companies and generic manufacturers. They must continue to innovate and protect their intellectual property to maintain their market position.
Major Acquisitions
GW Pharmaceuticals
- Year: 2021
- Acquisition Price (USD millions): 7200
- Strategic Rationale: Expanded Jazz's portfolio into cannabidiol-based medicines, particularly Epidiolex, diversifying revenue streams and bolstering its position in the neurology space.
Growth Trajectory and Initiatives
Historical Growth: Jazz Pharmaceuticals has grown through strategic acquisitions and product development.
Future Projections: Analyst projections suggest continued growth, driven by new product launches and market expansion.
Recent Initiatives: Recent initiatives include acquisitions to expand their oncology portfolio and continued development of their pipeline.
Summary
Jazz Pharmaceuticals shows strength in its established product portfolio and strategic acquisitions. The reliance on a few key products and exposure to generic competition pose challenges. Future growth hinges on successful pipeline development and expansion into new markets. Recent acquisitions enhance its oncology and neurology offerings, but careful management of debt is crucial.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Financial Reports
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jazz Pharmaceuticals PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2007-06-01 | President, CEO & Director Ms. Renee D. Gala | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2800 | Website https://www.jazzpharma.com |
Full time employees 2800 | Website https://www.jazzpharma.com | ||
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.